Figure 2.

The extracellular volume fraction (ECV) increased with the build‐up of interstitial fibrosis in the mice treated with l‐NAME, compared to l‐NAME+spironolactone. At baseline there were no significant differences in ECV between controls (“placebo”), l‐NAME, and l‐NAME+spironolactone groups. The ECV data for the control group are from a previous study, using the same experimental protocol. At follow‐up ECV was not significantly different between controls and l‐NAME+spironolactone (P=0.48). l‐NAME indicates Nω–nitro‐l‐arginine‐methyl‐ester.